Onco Wiki / Krankheit

Pankreas-Neuroendokrin-Tumor (pNET), gut differenziertes G1/G2

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDDIS-PNET
ArtErkrankung
Aliase
Funktionelles pNET (Insulinom, Gastrinom, Glucagonom, VIPom)Non-functional pNETPankreas-IsletzelltumorPankreas-Neuroendokrin-TumorpNETНейроендокринна пухлина підшлункової залози (пНЕП), добре-диференційована G1/G2
Statusreviewed 2026-05-03 | pending_clinical_signoff
ErkrankungenNone declared
QuellenSRC-NCCN-NET-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Quelle: YAML

icd_o_3_morphology8240/3
icd_o_3_topography["C25"]
icd_10C25.4
who_classificationWHO-Klassifikation für Verdauungssystem Tumore 5 ed (2019): Pankreasneuroendokriner Tumor G1 (Ki67 <3%), G2 (3–20%), G3 (>20%, aber gut differenziert)

Fähigkeiten

Anmerkungen

Well-differentiated pNET G1/G2 is the dominant subtype in clinical practice (non-functional, discovered incidentally or via abdominal mass/liver mets). Grading per WHO 2019: G1 Ki67 <3%, G2 Ki67 3–20%. G3 well-differentiated pNET (Ki67 >20%) occupies a grey zone — still well-differentiated morphologically but higher proliferation; NCCN recommends everolimus/sunitinib/SSA ± chemo; not modelled separately here (flagged via RF-NET-HIGH-GRADE-G3 for MDT review). Distinguishing from poorly differentiated NEC (ICD-O 8246/3) is essential: NEC requires platinum-etoposide chemotherapy (not SSA/TKI/mTOR). Key trials: RADIANT-3 (everolimus, Yao NEJM 2011), Raymond 2011 (sunitinib), CLARINET pNET subgroup (lanreotide). Surgery remains the only curative option for localized disease.

Verwendet von

Therapeutische Relevanz

Algorithmen

Erkrankung

Anwendungsgebiet

Verfahren

Fragebogen

Warnhinweis

Quellen